Home > PS Ratio > AUROBINDO PHARMA

AUROBINDO PHARMA
PS (Price/Sales) Ratio

The Current P/S Ratio of AUROBINDO PHARMA is 2.28.

Share Price ₹1,083.6Apr 24,2024
Market Cap ₹63,488.1 Cr
Sales-TTM₹27,894.7 CrTTM-Consolidated Results
Price/Sales2.28xCalculated as Market Cap/Sales
Explore Stock Analytics
COMMUNITY POLL
for AUROBINDO PHARMA
Please provide your vote to see the results
AUROBINDO PHARMA is part of below Screeners ↓
Best Quarterly Growth Mid Cap Stocks

Definition & Calculation of PS (Price/Sales) ratio of AUROBINDO PHARMA

Price-to-Sales ratio, P/S Multiple, or P/S Ratio is an important valuation multiple that is defined as:

P/S = Market Capitalization / Sales

or, using per-share numbers:

P/S = Stock Price / Sales Per Share

Applying the above formula, P/S ratio of AUROBINDO PHARMA is calculated as :

Current Market Cap [ ₹63,488.1 Cr] as on Apr 24,2024

(/) Sales [ ₹27,894.7 Cr] based on TTM-Consolidated Results

(=) P/S Ratio [ 2.28x ]

P/S Ratio indicates 'the multiple of sales' investors are willing to pay to own one share of the company.

Thus, for AUROBINDO PHARMA , the investors are currently willing to pay '2.28 times sales' to own 1 share of the company.

PS Multiples are one of the most widely used valuation multiple in the industry.

P/S ratios can be a reliable benchmark to compare companies with negative earnings or book value.

You may also explore Price to Earnings ratio or Price to Book ratio of AUROBINDO PHARMA !

The chart below summarizes the trend in P/S Ratio of AUROBINDO PHARMA over the last five years.

Historical PS (Price/Sales) ratio chart of AUROBINDO PHARMA


PS Ratio Performance Analysis for AUROBINDO PHARMA

- AUROBINDO PHARMA 's latest p/e ratio is 2.28x.

- AUROBINDO PHARMA 's p/e ratio for fiscal years ending Mar2023 to Mar2019 averaged 1.67x.

- AUROBINDO PHARMA 's operated at median p/e ratio of 1.67x from fiscal years ending March 2018 to 2022.

- Looking back at the last 5 fiscal years, AUROBINDO PHARMA 's p/e ratio peaked in Mar2019 at 2.35x.

- AUROBINDO PHARMA 's p/e ratio hit its five-year low in Mar2020 of 1.05x.


How does AUROBINDO PHARMA 's P/S Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?

Peer Comparison (Pharmaceuticals & Drugs Industry)Sales (Cr)PS RatioMarket Cap (Cr)
AUROBINDO PHARMA 27,894.72.2863,488.1
SUN PHARMACEUTICAL INDUSTRIES LTD47,444.67.52356,625.0
CIPLA LTD25,350.24.46112,938.0
DR REDDYS LABORATORIES LTD27,212.53.6599,276.9
ZYDUS LIFESCIENCES LTD19,024.24.9493,921.9
DIVIS LABORATORIES LTD7,492.813.52101,315.0
MANKIND PHARMA LTD9,946.39.6796,143.2
TORRENT PHARMACEUTICALS LTD10,474.08.6890,872.6
LUPIN LTD19,480.13.7072,010.8
ABBOTT INDIA LTD5,753.49.4054,105.4
ALKEM LABORATORIES LTD12,634.44.4656,337.8

Pharmaceuticals & Drugs Industry Benchmark (Top 10) PS Analysis vs AUROBINDO PHARMA 's P/S Ratio

Top 10 Industry PeersPS Ratio
Min industry PS 2.28x
Max industry PS 13.52x
Median industry PS 4.94x
Average industry PS 6.57x



You may also like the below Video Courses